Ascend Montclair Pharmacy Launches Medical CBD SalesNote

Aug.22.2022
Ascend Montclair Pharmacy Launches Medical CBD SalesNote
Ascend Montclair pharmacy launched medical CBD last weekend, drawing in a steady crowd of customers.

Last Saturday, Ascend Montclair pharmacy launched medical CBD products during their weekend sale, attracting a steady stream of customers to the pharmacy.

 

Michele DeZao, a 60-year-old from Rockaway, was also among those who came to inspect. Two months ago, she obtained a medical CBD card and this was her second time visiting the pharmacy.

 

The cancer-disabled patient in recovery immediately noticed that the crowd on Saturday was increasing. However, she was relieved to have received priority treatment in the queue reserved only for medical patients to be discharged.

 

The hours between 8am to 10am are reserved exclusively for medical patients, while adult tobacco purchases begin at 10am every day of the week at Ascend Montclair.

 

I have no problem," Dezo said while paying, claiming it helps alleviate stomach pain. "Anyway, people are buying it (adult tobacco), so why not make it legal?

 

On August 20, 2022, Michele DeZao picked up her medical marijuana from Ascend Montclair pharmacy. The pharmacy, located at 395 Bloomfield Avenue, officially opened its doors on Friday at 10am and became the 19th pharmacy in New Jersey to sell adult-use cannabis after weeks of negotiations with the town. Alexandra Pais of NJ Advance Media captured the moment.

 

We appreciate the support of the Montclair community and are excited to share the Ascend experience with people in Montclair and surrounding towns," said Caitlin Fleishman, Public Affairs and Communications Director for Ascend Wellness, the multi-state operator of the pharmacy.

 

Last Tuesday, the Montclair Township administration voted 5-1 in favor of a pre-negotiated settlement agreement with Ascend, allowing for the sale of adult tobacco products.

 

Peter Yacobellis, the town consultant, stated that as part of the settlement agreement, Ascend Montclair will provide "voluntary donations" to various organizations using revenue from adult tobacco sales.

 

In an email, Yacobellis praised Ascend for their incredible generosity towards the citizens of Montclair, particularly their contributions to the Montclair Community Development Corporation and the Montclair Pre-K program. Yacobellis also emphasized the importance of ensuring that low-income and communities of color benefit from the revenue generated by the new cannabis market, as these communities have been disproportionately impacted by legacy marijuana laws.

 

The owner and co-founder of Ascend announced that another New Jersey location in Roselle Park launched adult tobacco sales statewide on April 21 and quickly became one of their top-performing adult cannabis stores in the U.S.

 

Ascend Fort Lee began selling medical marijuana on August 12th and plans to expand into adult CBD in the fall.

 

At Ascend Montclair, "there is a lot of traffic and support," said Fleishman.

 

Statement:

 

This article is compiled from third-party information and is intended solely for industry professionals for discussion and study purposes.

 

This article does not represent the views of 2FIRSTS, nor can 2FIRSTS confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry exchange and research.

 

Due to limitations in translation ability, this article may not accurately reflect the meaning of the original text. Please refer to the original text for accuracy.

 

2FIRSTS is in full agreement with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan or international issues and positions.

 

The compilation information is the property of the original media and author. If there is any infringement, please contact us for deletion.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australia’s Coalition has unveiled a national illicit-tobacco policy that would cut tobacco excise by 80% and create legal, regulated and taxed adult markets for vaping products and nicotine pouches if it wins government. The plan proposes an excise of A$0.50 per millilitre of e-liquid and A$0.025 per milligram of nicotine in pouches, alongside A$200 million in additional enforcement and a A$60 million three-year public-awareness campaign. The Coalition says the package would narrow the price advantage of illicit products and undermine organised crime, while Labor and public-health groups warn that dramatically cheaper cigarettes could reverse long-term declines in smoking.
Sep.03
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04